148 related articles for article (PubMed ID: 16681805)
1. In vitro investigations on the mode of action of the hydroxypyridone antimycotics rilopirox and piroctone on Candida albicans.
Sigle HC; Schäfer-Korting M; Korting HC; Hube B; Niewerth M
Mycoses; 2006 May; 49(3):159-68. PubMed ID: 16681805
[TBL] [Abstract][Full Text] [Related]
2. Oxygen accessibility and iron levels are critical factors for the antifungal action of ciclopirox against Candida albicans.
Sigle HC; Thewes S; Niewerth M; Korting HC; Schäfer-Korting M; Hube B
J Antimicrob Chemother; 2005 May; 55(5):663-73. PubMed ID: 15790671
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Candida albicans adhesiveness to human buccal and vaginal cells by sub-inhibitory concentrations of rilopirox.
Braga PC; Dal Sasso M; Maci S; Piatti G; Dannhorn DR; Bohn M
Arzneimittelforschung; 1995 Jan; 45(1):84-7. PubMed ID: 7893277
[TBL] [Abstract][Full Text] [Related]
4. Alterations in surface morphology of Candida albicans produced by rilopirox: a scanning electron microscopy study.
Braga PC; Maci S; Dal Sasso M; Piatti G; Bohn M
J Chemother; 1995 Dec; 7(6):519-24. PubMed ID: 8667036
[TBL] [Abstract][Full Text] [Related]
5. Rilopirox--a new hydroxypyridone antifungal with fungicidal properties.
Raether W; Hänel H
Mycoses; 1990 Apr; 33(4):191-202. PubMed ID: 2233892
[TBL] [Abstract][Full Text] [Related]
6. [Mode of action of ciclopiroxolamine on Candida albicans].
Niewerth M; Schaller M; Korting HC; Hube B
Mycoses; 2002; 45 Suppl 1():63-8. PubMed ID: 12073566
[TBL] [Abstract][Full Text] [Related]
7. [In vitro antifungal activity of rilopirox, a new hydroxypyridone antimycotic agent].
Harada I; Mitsui K; Uchida K; Yamaguchi H
Jpn J Antibiot; 1997 Feb; 50(2):195-9. PubMed ID: 9100079
[TBL] [Abstract][Full Text] [Related]
8. [The mode of action of imidazole antimycotics: implications for sensitivity testing (author's transl)].
Haller I
Mykosen; 1979 Dec; 22(12):423-30. PubMed ID: 396473
[No Abstract] [Full Text] [Related]
9. [The in vitro properties of a new hydroxypyridone antimycotic rilopirox, with special reference to its anti-Candida activity].
Harada I; Mitsui K; Uchida K; Yamaguchi H
Jpn J Antibiot; 1999 Feb; 52(2):146-52. PubMed ID: 10221179
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of a series of piperazine-1-carboxamidine derivatives with antifungal activity resulting from accumulation of endogenous reactive oxygen species.
François IE; Thevissen K; Pellens K; Meert EM; Heeres J; Freyne E; Coesemans E; Viellevoye M; Deroose F; Martinez Gonzalez S; Pastor J; Corens D; Meerpoel L; Borgers M; Ausma J; Dispersyn GD; Cammue BP
ChemMedChem; 2009 Oct; 4(10):1714-21. PubMed ID: 19705386
[TBL] [Abstract][Full Text] [Related]
11. Effect of filamentation and mode of growth on antifungal susceptibility of Candida albicans.
Watamoto T; Samaranayake LP; Jayatilake JA; Egusa H; Yatani H; Seneviratne CJ
Int J Antimicrob Agents; 2009 Oct; 34(4):333-9. PubMed ID: 19376687
[TBL] [Abstract][Full Text] [Related]
12. Antifolates as antimycotics? Connection between the folic acid cycle and the ergosterol biosynthesis pathway in Candida albicans.
Navarro-Martínez MD; Cabezas-Herrera J; Rodríguez-López JN
Int J Antimicrob Agents; 2006 Dec; 28(6):560-7. PubMed ID: 17046206
[TBL] [Abstract][Full Text] [Related]
13. In vitro antifungal activity of 2,5 disubstituted amino-oksometyloso-arylo-thiadiazole derivatives.
Lukaszuk C; Krajewska-Kułak E; Niewiadomy A; Stachowicz J; Głaszcz U; Oksiejczuk E
Adv Med Sci; 2007; 52 Suppl 1():26-9. PubMed ID: 18229628
[TBL] [Abstract][Full Text] [Related]
14. Ultrastructural investigations of Candida albicans after in vitro treatment with the new fungicidal agent rilopirox.
Reitze HK; Dannhorn DR; Hänel H; Seitz KA
Mycoses; 1993; 36(11-12):385-95. PubMed ID: 7935570
[TBL] [Abstract][Full Text] [Related]
15. Reactive oxygen species play no role in the candidacidal activity of the salivary antimicrobial peptide histatin 5.
Veerman EC; Nazmi K; Van't Hof W; Bolscher JG; Den Hertog AL; Nieuw Amerongen AV
Biochem J; 2004 Jul; 381(Pt 2):447-52. PubMed ID: 15109304
[TBL] [Abstract][Full Text] [Related]
16. Studies for the elucidation of the mode of action of the antimycotic hydroxypyridone compound, rilopirox.
Kruse R; Hengstenberg W; Hänel H; Raether W
Pharmacology; 1991; 43(5):247-55. PubMed ID: 1664523
[TBL] [Abstract][Full Text] [Related]
17. The alternative oxidase of Candida albicans causes reduced fluconazole susceptibility.
Yan L; Li M; Cao Y; Gao P; Cao Y; Wang Y; Jiang Y
J Antimicrob Chemother; 2009 Oct; 64(4):764-73. PubMed ID: 19656781
[TBL] [Abstract][Full Text] [Related]
18. Damage to the cytoplasmic membrane and cell death caused by lycopene in Candida albicans.
Sung WS; Lee IS; Lee DG
J Microbiol Biotechnol; 2007 Nov; 17(11):1797-804. PubMed ID: 18092463
[TBL] [Abstract][Full Text] [Related]
19. Serum or bile affects the in vitro azole susceptibilities of Candida spp.
Nagi M; Tanabe K; Takano Y; Kikuchi K; Miyazaki Y; Niimi M
Jpn J Infect Dis; 2009 Jul; 62(4):306-8. PubMed ID: 19628912
[TBL] [Abstract][Full Text] [Related]
20. Antifungal activity of Morinda citrifolia fruit extract against Candida albicans.
Jainkittivong A; Butsarakamruha T; Langlais RP
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Sep; 108(3):394-8. PubMed ID: 19716507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
